The Department of Health – Abu Dhabi (DoH), the emirate of Abu Dhabi’s regulatory body for the healthcare sector, and G42 Healthcare, an Abu Dhabi-based leading health tech company and subsidiary of G42, an artificial intelligence and cloud computing company, have signed a letter of intent (LOI) with global biopharmaceutical company AstraZeneca. The LOI aims to expand their collaboration into the domains of diagnostics and clinical research, provide
Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.
G42 Healthcare and AstraZeneca initially signed a Declaration of Collaboration in December 2021. This agreement further expands on their partnership to build local research capabilities, conduct RWE / clinical trials in UAE and localize Oncology biomarkers testing in UAE.
“We value collaboration and believe the strategic partnership with AstraZeneca will yield incredible growth for the healthcare ecosystem. We are proud to align ourselves with these organizations to generate new treatments and technologies to solidify the UAE’s place as a global hub for life sciences, medical tourism and innovation.”
Ashish Koshy, CEO of G42 Healthcare
“We are excited about expanding our existing partnership with G42 Healthcare to further advance the healthcare sector in the country and region. There is no doubt that innovation is key to healthcare advancements, and we are eagerly looking forward to collaboratively exploring greater possibilities in clinical research and diagnostics, enabling us to together create a more patient-centric healthcare offering in the UAE.”
Hicham Mirghani, Corporate Affairs Director GCC, AstraZeneca
